NASDAQ:CRTX - Cortexyme Stock Price, Forecast & News

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Cortexyme, Inc. (NASDAQ:CRTX) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.00. View Cortexyme's Earnings History.

Cortexyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Cortexyme.

3 brokers have issued 1 year price targets for Cortexyme's stock. Their forecasts range from $14.00 to $53.00. On average, they anticipate Cortexyme's stock price to reach $34.25 in the next year. This suggests that the stock has a possible downside of 41.8%. View Analyst Price Targets for Cortexyme.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.

News coverage about CRTX stock has been trending very positive on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cortexyme earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Cortexyme.

Cortexyme saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,550,000 shares, an increase of 39.6% from the December 15th total of 1,110,000 shares. Based on an average daily volume of 160,100 shares, the short-interest ratio is presently 9.7 days. Approximately 17.2% of the shares of the stock are sold short. View Cortexyme's Current Options Chain.

Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Alibaba Group (BABA), Honeywell International (HON), Thermo Fisher Scientific (TMO), Home Depot (HD), Cisco Systems (CSCO), CVS Health (CVS), Verizon Communications (VZ), Procter & Gamble (PG), Johnson & Johnson (JNJ) and Raytheon (RTN).

(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRTX stock can currently be purchased for approximately $58.88.

Cortexyme has a market capitalization of $1.58 billion. Cortexyme employs 16 workers across the globe.View Additional Information About Cortexyme.

The official website for Cortexyme is http://www.cortexyme.com/.

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]